Anavex Life Sciences Corp (AVXL)

[Doc328]

If Excellence (ages 5-17) had been successful, the Avatar small adult trial probably would have been sufficient to convince regulatory agencies to approve for all ages and not just pediatric.

Avatar did not report the FDA preferred endpoints (coprimary RSBQ and CGI-I change over 12 weeks time) but rather reported a different related endpoint (responder analysis over 7 weeks). Without that success, I do not think the Avatar data helps for approval.